Navigation Links
Amsterdam Molecular Therapeutics Part of Next Biotech Index
Date:4/8/2008

AMSTERDAM, The Netherlands, April 8 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, is, as of today, part of the newly created Next Biotech Index of NYSE Euronext. "We are pleased that NYSE Euronext has selected our company for this index," said Ronald Lorijn, CEO of AMT. "The index will increase the visibility of listed biotech companies and will help investors to track the performance of our sector."

The index is published daily on http://www.euronext.com as well as major data vendors. The ticker symbol is BIOTK.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
2. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Molecular Vision and Acrongenomics Unable to Reach Agreement on the Acquisition of Molecular Vision
8. Roche Molecular Diagnostics Invests $57.5 Million in Green Research Building
9. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
10. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , ... and prevention of high-burden diseases, and Centric Consulting, a business and technology consulting ... utilize existing data in order to identify and prioritize patients for care. , ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... data insights, today announced that the launch of a new clinical ... data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service ...
Breaking Biology Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the ... ProText™, making them the first Wharton’s jelly allografts to be assigned a Q code ... solutions are the first Wharton’s jelly allograft product to be recognized as a 361 ...
(Date:7/31/2020)... FREDERICK, Md. (PRWEB) , ... July 30, 2020 ... ... Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & ... goal of this project is to develop, optimize, and scale-up a highly efficient ...
(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
Breaking Biology News(10 mins):